Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at StockNews.com

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research report report published on Tuesday morning.

COLL has been the topic of a number of other reports. Needham & Company LLC reissued a buy rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Truist Financial boosted their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a buy rating in a report on Monday, February 26th. Piper Sandler reissued an overweight rating and set a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, Jefferies Financial Group reissued a hold rating and set a $37.00 target price (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $39.00.

Collegium Pharmaceutical Trading Up 1.0 %

NASDAQ COLL opened at $35.84 on Tuesday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of 30.37 and a beta of 1.03. The stock’s 50 day moving average price is $37.06 and its two-hundred day moving average price is $31.18. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. Collegium Pharmaceutical has a 52 week low of $20.83 and a 52 week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. As a group, analysts anticipate that Collegium Pharmaceutical will post 5.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COLL. SG Americas Securities LLC bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at $221,000. Strs Ohio lifted its position in shares of Collegium Pharmaceutical by 1,650.0% during the 3rd quarter. Strs Ohio now owns 21,000 shares of the specialty pharmaceutical company’s stock valued at $469,000 after acquiring an additional 19,800 shares during the period. Inspire Investing LLC lifted its position in shares of Collegium Pharmaceutical by 3.2% during the 3rd quarter. Inspire Investing LLC now owns 27,840 shares of the specialty pharmaceutical company’s stock valued at $622,000 after acquiring an additional 873 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Collegium Pharmaceutical by 1,019.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,670 shares of the specialty pharmaceutical company’s stock valued at $931,000 after acquiring an additional 37,946 shares during the period. Finally, Los Angeles Capital Management LLC lifted its position in shares of Collegium Pharmaceutical by 0.8% during the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock valued at $1,718,000 after acquiring an additional 585 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.